In patients with HIV-associated stage II-IV cHL, treatment with BV plus doxorubicin, vinblastine, and dacarbazine was associated with an increase compared to baseline in CD4+ and CD8+ T-cell counts 1 month after treatment initiation.36 The elevation continued during treatment despite lymphotoxic therapy. This evidence concerns the gene CD4 and classic Hodgkin lymphoma.